Search tips
Search criteria 


Logo of hccpBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleHereditary Cancer in Clinical PracticeJournal Front Page
Hered Cancer Clin Pract. 2010; 8(Suppl 1): O5.
Published online 2010 May 25. doi:  10.1186/1897-4287-8-S1-O5
PMCID: PMC2876277

Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy



The CAPP2 Study evaluated 600mg enteric coated aspirin and/or 30gms of Novelose (resistant starch) in a double blind factorial RCT in 1071 carriers of Lynch syndrome over a treatment period of 1 to 4 years, mean 29 months.


The trial, reported in December 2008 [1], showed that there was no difference between the treatment and placebo groups for new colorectal neoplasia. Follow-up data for 667 participants for up to 120 months (mean 51m) is now available. Analysis reveals a striking reduction in subsequent cancers; overall, 102 participants have developed 110 Lynch syndrome cancers. Despite equal numbers being randomised to aspirin or placebo, cancer sufferers in the aspirin group are outnumbered 2 to 1. Lifetable analysis for time to first Lynch syndrome cancer reveals a hazard ration of 0.62(0.41, 0.96)p=0.03. There is a clear effect of duration of treatment: <24months on treatment OR 0.90 (0.45, 1.81) p=0.78, treated >24 months OR 0.50 (0.28, 0.86) p=0.01.


All carriers of Lynch syndrome should consider aspirin chemoprevention. A dose finding study, CAPP3, is under development. It will compare different doses of aspirin over a 5 to 10 year period.

Funding provided by the UK Medical Research Council, Cancer Research UK, EU Framework and Bayer Corp.


  • Bum J, Bishop DT, Mecklin JP. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch Syndrome. NEJM. 2008;359(24):2567–78. doi: 10.1056/NEJMoa0801297. [PubMed] [Cross Ref]

Articles from Hereditary Cancer in Clinical Practice are provided here courtesy of BioMed Central